Gout Management in Chronic Kidney Disease: Pearls and Pitfalls

Gout Management in Chronic Kidney Disease: Pearls and Pitfalls:

Abstract

Purpose of review

Gout is more prevalent than ever and is associated with multiple chronic comorbidities, including Chronic Kidney Disease (CKD). While goals of treatment are the same as in those without renal impairment, co-morbid CKD poses a challenge in treatment selection and requires a solid understanding of potential drug-drug interaction and drug-related toxicity.

Recent findings

In acute gout complicated by CKD, NSAIDs should be avoided, and colchicine used with caution. Systemic corticosteroids are effective but may be replaced by anakinra, in particular in inpatients with additional comorbidities that may make corticosteroids less desirable. Allopurinol remains the first line urate lowering therapy (ULT), starting at a low dose followed by careful goal driven up-titration. Febuxostat is a reasonable alternative, though second line in light of recent cardiovascular data. Uricosuric drugs are generally less effective, while pegloticase is reserved for refractory cases of polyarticular tophaceous disease.

Summary

Gout treatment must be guided by renal function but in spite of renal disease can be successfully managed.